Press Releases

Tel Aviv—April 5, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the listing of the Company’s 4,279,288 previously issued Series B warrants on the NYSE MKT (the “Exchange”).  Beginning at the market open April 10, 2017, the… Read More

Tel Aviv—April 4, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it has signed an agreement with Ada Medikal Ltd. Sti, a leading medical distributor in Turkey, to distribute CGuardTM EPS (Embolic Prevention System). Agustin Gago, EVP… Read More

BOSTON, MA—March 30, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the launch of its CGuardTM Embolic Prevention System (EPS) at the ICCA Stroke Conference 2017 held March 24th-25th at the Vishnevskiy Institute of Surgery of the… Read More

BOSTON, MA—March 23, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced that its CGuard™ Carotid Embolic Prevention System will be featured at the ICCA Stroke 2017 to be held March 24th-25th at the Vishnevskiy Institute of Surgery of… Read More

Tel Aviv—March 22, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it has repaid the remaining balance of $1.2 million on its term loan facility with Hercules Technology Growth Capital, Inc.  All liens and security interests… Read More

BOSTON, MA—March 21, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it has signed a distribution agreement for CGuard™ EPS with a distributor partner in Hong Kong. Agustin Gago, EVP and Chief Commercial Officer of InspireMD, commented,… Read More

Tel Aviv—March 20, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it has signed an agreement with Nerin Assets OU (“Nerin”), a leading regional distributor, covering the Russian Federation to distribute CGuardTM EPS (Embolic Prevention System). Agustin… Read More

Announces Agreements with Leading Distributors in the Baltic States   BOSTON, MA—March 15, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it has signed agreements with distributors in Estonia, Lithuania and Latvia as part of its strategy… Read More

BOSTON, MA – March 14, 2017 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the closing of a “best efforts” public offering of 1,069,822 shares of Series C Convertible Preferred Stock, Series B warrants to purchase 4,279,288… Read More

BOSTON, MA – March 9, 2017 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the pricing of a “best efforts” public offering of up to 1,171,875 shares of Series C Convertible Preferred Stock, Series B warrants to… Read More